New covalent inhibitor targets DNAJC9 to reduce sepsis inflammation
This new article publication from Acta Pharmaceutica Sinica B discusses the discovery of the covalent inhibitor A12 and the identification of DNAJC9 as a potential drug target for sepsis-associated inflammation.
Read original article on The Medical News →Related news
-
A self-charging toothbrush that generates electricity to kill bacteria while you brush
United Kingdom
-
'Genetic map' of patient's tumor uncovers cancer risk genes that would otherwise remain hidden
United Kingdom
-
New blood count ranges could prevent unnecessary testing for people with Duffy-null trait
United Kingdom
-
First-time homebuyers remain scarce, but a record share of them pay all cash
United States
-
Scientists pinpoint hundreds of genetic variants that offer new insights into inherited breast cancer risk
United Kingdom
-
Stronger cholesterol treatment shrinks more plaque in heart arteries, new clinical trial finds
United Kingdom
-
Compound YZG-331 leverages gut microbiota to improve sleep in mouse models of insomnia
United Kingdom
-
Anti-PEG antibodies drive contrasting liposome skin toxicity across species
United Kingdom